Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question.
Both Lilly and its competitor, Denmark’s Novo Nordisk, which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications. There is no quick fix for that given the complexity of building out manufacturing capacity for the injections. Both companies are investing billions of dollars a year to try to catch up.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
24World Media does not take any responsibility of the information you see on this page. The content this page contains is from independent third-party content provider. If you have any concerns regarding the content, please free to write us here: contact@24worldmedia.com
Lynnfield, Marblehead football teams reach the end of the road
Police Logs 11-16-24 – Itemlive
Catalyst Housing offers supportive living
Lynn Tech’s Festival of Trees grows to 10
Nahant Lions Club takes aim at Turkey Shoot
Salem State staff rallies for teacher strikes
Saugus School Committee passes budget amendment
Kelli Francine Mealy – The Suffolk Times
‘Spamalot’ kicks off NFCT community theater season
Shribman: What’s to come for Trump 2.0
Editorial: Missouri’s House speaker fight highlights two competing strains of Republicanism
Molina: Trump’s border czar and a history we should not forget